Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
@OncimmuneECDT @bmj_latest @primarycare_sta @FrancesMair @NHSLanarkshire The inimitable Karena & some photos of the night @primarycare_sta
@OncimmuneECDT @bmj_latest Looking forward to this tonight. Maybe a chance to meet some of the people we helped through this work, making the effort over the years worthwhile....
@primarycare_sta @FrancesMair @NHSLanarkshire
Thank you to @bmj_latest for the feature on 'Extra Time' in this week's edition of the journal. 'Extra Time' is now showing at Proud Central Gallery, 32 John Adam St, London WC2N 6BP.
On BBC East Midlands on Monday, journalist and lifelong smoker Al Needham volunteers to have the EarlyCDT blood test. You can watch it here: http://bbc.in/2SyVQQP @bbcemt
Here's CEO Adam Hill talking to Al on the rooftop of our London office.
#lungcancer #lungcancerscreening
This week was #WorldCancerDay. #TBT to our interview with Dr Adam Hill, CEO of Oncimmune on early detection of #cancer #biomarkers.
Tune in now: https://jo.my/76t
#digitalhealth @healthpodnet @OncimmuneECDT
"But there is a simple, cost-effective blood test available which, in combination with low-dose CT scanning, has the potential to detect tumours up to nine years earlier than a scan alone." ECLS staff Pauline Armory and Maxine Arnott in @guardian letters today.
"It is a tragedy that lung cancer rates are over 80% higher in the most deprived areas of the UK – and that detection rates vary by more than 20% from region to region." Pauline Armory and Maxine Arnott from the ECLS trial in letters to The @guardian today #lungcancerscreening
Oncimmune Scottish Study Results Could Fuel Move Into Screening as Firm Eyes CDx Opportunities
Oncimmune Scottish Study Results Could Fuel Move Into Screening as
The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift...
www.360dx.com
Gallery
